Barbara L. Jones


B-Cell Malignancies: Transforming Expectations and Outcomes

January 6th 2014

With the arrival and incorporation into clinical practice of immunomodulatory drugs (IMiDs) and proteasome inhibitor therapy, patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer.

Model Emerges for Targeting Oncogenes in NSCLC

December 30th 2013

Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of non-small cell lung cancer, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of anaplastic lymphoma kinase.

Studies Highlight Newly Approved and Novel Multiple Myeloma Treatments

July 26th 2013

Researchers highlighted the latest developments in the treatment of multiple myeloma at the 2013 ASCO Annual Meeting. Noteworthy abstracts included updated data on pomalidomide, as well as research involving the novel agents daratumumab and elotuzumab.

Value-Based Purchasing: How Physicians Will Be Compensated in the Future

May 10th 2013

An interview with Frank G. Opelka, MD, exploring some of the health policy initiatives that will impact how physicians will be compensated in the future.

Studies Determine Smokers' Risks of Recurrence, Progression, and Survival in Bladder Cancer

March 20th 2013

An international group of investigators provided first-time evidence of the impact of smoking on outcomes in bladder cancer in results from two studies.

RARP Oncologic Outcomes Equivalent to Open Surgery for High-Risk Prostate Tumors

March 14th 2013

A novel retrospective study comparing robot-assisted radical prostatectomy and radical retropubic prostatectomy, in men with high-risk prostate cancer, found equivalent oncologic outcomes.

Active Surveillance Safe Primary Management Strategy for Patients With Low-Grade Prostate Cancer

March 4th 2013

Treatment can safely be delayed in patients with low-grade prostate cancer who are carefully selected but then demonstrate disease progression after a period of active surveillance.

Targeted Therapies, Multidrug Regimens, and Standardized Drug Development Efforts Needed in Nonmuscle-Invasive Bladder Cancer

February 26th 2013

Collaborative and standardized efforts to develop and evaluate novel drugs are necessary to ultimately provide effective long-term treatment for nonmuscle-invasive bladder cancer.

Partial Nephrectomy Remains Underutilized, Despite AUA Endorsement

February 26th 2013

Although the 2009 AUA guidelines cite "compelling data" for consideration of nephron-sparing surgery in all patients, partial nephrectomy remains underutilized for small renal masses.

Multidisciplinary Prostate Cancer Care at Duke Cancer Institute: An Interview With Judd W. Moul, MD

January 16th 2013

Judd W. Moul, MD, from the Duke Cancer Institute, comments on practice trends in urologic cancer care and the advantages and disadvantages of his institution's multidisciplinary prostate cancer clinic.

Urology Practices Organize to Deliver Comprehensive Cancer Care: An Interview With Daniel R. Saltzstein, MD

October 22nd 2012

Daniel R. Saltzstein, MD, describes steps Urology San Antonio has taken toward creation of a comprehensive urologic care practice, including establishment of a bone health clinic and an advanced prostate cancer clinic.